A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study.

MLA

Robins, H., et al. “A Randomized Phase I/II Study of ABT-888 in Combination with Temozolomide in Recurrent Temozolomide Resistant Glioblastoma: An NRG Oncology RTOG Group Study.” Journal of Neuro-Oncology, vol. 126, no. 2, Jan. 2016, pp. 309–16. EBSCOhost, https://doi.org/10.1007/s11060-015-1966-z.

APA

Robins, H., Zhang, P., Gilbert, M., Chakravarti, A., Groot, J., Grimm, S., Wang, F., Lieberman, F., Krauze, A., Trotti, A., Mohile, N., Kee, A., Colman, H., Cavaliere, R., Kesari, S., Chmura, S., & Mehta, M. (2016). A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study. Journal of Neuro-Oncology, 126(2), 309–316. https://doi.org/10.1007/s11060-015-1966-z

Chicago

Robins, H., Peixin Zhang, Mark Gilbert, Arnab Chakravarti, John Groot, Sean Grimm, Fen Wang, et al. 2016. “A Randomized Phase I/II Study of ABT-888 in Combination with Temozolomide in Recurrent Temozolomide Resistant Glioblastoma: An NRG Oncology RTOG Group Study.” Journal of Neuro-Oncology 126 (2): 309–16. doi:10.1007/s11060-015-1966-z.